The Nuvaxovid (Novavax) vaccine is included in the SarsCoV2 / Covid-19 vaccination program currently for the primary course only
, along with vaccines already authorized for use in the European Union.
Nuvaxovid is administered intramuscularly as a course of 2 doses (0.5 mL each) 3 weeks (21 days) apart.
This is highlighted by the circular of the Ministry of Health 'Indication of use of the anti COVID-19 Nuvaxovid (Novavax) vaccine in subjects aged 18 and over', signed by the Director of Prevention of the ministry Gianni Rezza.
On 22/12/2021, it is emphasized in the circular of the ministry, the Technical Scientific Commission of AIFA, accepting the opinion expressed by the European Medicines Agency (EMA), approved the indication of use of the Nuvaxovid (Novavax) vaccine, in the specific formulation for injection of 0.5 mL / dose, starting from 18 years of age.
Each Nuvaxovid multidose vial is 10 doses of 0.5 mL, requires no dilution and is therefore ready to use.
The closed vial, stored in the refrigerator at a temperature between 2 ° C and 8 ° C, is valid for 9 months.
The closed vial, at room temperature up to 25 ° C, is usable within 12 hours.
After the first perforation, the vial can be stored at 2 ° C to 25 ° C and is usable within 6 hours.
